Abstract
The metabolism of radiolabeled antibodies is important for radioimmunoimaging and therapy. The loss of indium-111 (111In) from the chelate can pose problems in imaging and increases the radiation dose to normal tissues. We have evaluated the loss in vivo of 111In from Lym-1-benzyl-EDTA-111In (an antibody conjugated with isothiocyanatobenzyl-EDTA) in normal mice. A monoclonal antibody (CHA 255) that binds to benzyl-EDTA-indium chelates, but not to other forms of indium, was used to measure the percent of 111In remaining in the chelate. Four days after injection, 97.4 ± 2.2% of the 111In in the liver was still in the benzyl-EDTA chelate, as was 99.4 ± 0.7% of the 111In in the urine, and 99.1 ± 0.7% of the 111In in the blood. Studies in vitro indicate that a benzyl-EDTA-111In-antibody-chelate conjugate is more stable in human serum than a benzyl-DTPA-111In conjugate, and that both benzyl-chelate conjugates are much more stable than an unsubstituted DTPA conjugate.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 218-224 |
| Number of pages | 7 |
| Journal | Journal of Nuclear Medicine |
| Volume | 31 |
| Issue number | 2 |
| State | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
Cite this
Metabolism of indium chelates attached to monoclonal antibody : Minimal transchelation of indium from benzyl-EDTA chelate in vivo. / Deshpande, S. V.; Subramanian, R.; McCall, M. J.; DeNardo, S. J.; Denardo, Gerald L; Meares, C. F.
In: Journal of Nuclear Medicine, Vol. 31, No. 2, 1990, p. 218-224.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metabolism of indium chelates attached to monoclonal antibody
T2 - Minimal transchelation of indium from benzyl-EDTA chelate in vivo
AU - Deshpande, S. V.
AU - Subramanian, R.
AU - McCall, M. J.
AU - DeNardo, S. J.
AU - Denardo, Gerald L
AU - Meares, C. F.
PY - 1990
Y1 - 1990
N2 - The metabolism of radiolabeled antibodies is important for radioimmunoimaging and therapy. The loss of indium-111 (111In) from the chelate can pose problems in imaging and increases the radiation dose to normal tissues. We have evaluated the loss in vivo of 111In from Lym-1-benzyl-EDTA-111In (an antibody conjugated with isothiocyanatobenzyl-EDTA) in normal mice. A monoclonal antibody (CHA 255) that binds to benzyl-EDTA-indium chelates, but not to other forms of indium, was used to measure the percent of 111In remaining in the chelate. Four days after injection, 97.4 ± 2.2% of the 111In in the liver was still in the benzyl-EDTA chelate, as was 99.4 ± 0.7% of the 111In in the urine, and 99.1 ± 0.7% of the 111In in the blood. Studies in vitro indicate that a benzyl-EDTA-111In-antibody-chelate conjugate is more stable in human serum than a benzyl-DTPA-111In conjugate, and that both benzyl-chelate conjugates are much more stable than an unsubstituted DTPA conjugate.
AB - The metabolism of radiolabeled antibodies is important for radioimmunoimaging and therapy. The loss of indium-111 (111In) from the chelate can pose problems in imaging and increases the radiation dose to normal tissues. We have evaluated the loss in vivo of 111In from Lym-1-benzyl-EDTA-111In (an antibody conjugated with isothiocyanatobenzyl-EDTA) in normal mice. A monoclonal antibody (CHA 255) that binds to benzyl-EDTA-indium chelates, but not to other forms of indium, was used to measure the percent of 111In remaining in the chelate. Four days after injection, 97.4 ± 2.2% of the 111In in the liver was still in the benzyl-EDTA chelate, as was 99.4 ± 0.7% of the 111In in the urine, and 99.1 ± 0.7% of the 111In in the blood. Studies in vitro indicate that a benzyl-EDTA-111In-antibody-chelate conjugate is more stable in human serum than a benzyl-DTPA-111In conjugate, and that both benzyl-chelate conjugates are much more stable than an unsubstituted DTPA conjugate.
UR - http://www.scopus.com/inward/record.url?scp=0025099617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025099617&partnerID=8YFLogxK
M3 - Article
VL - 31
SP - 218
EP - 224
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 2
ER -